Filing Flows › Health Care › Apyx Medical (APYX)
Apyx Medical (APYX) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Apyx Medical (APYX) Q3 2026 earnings results →
Q3 2026 Revenue up 9% year over year to $14.0M · 13¢ of every $1 of revenue lost · operating margin -4.1%
Apyx Medical made $14.0M in Q3 2026 (+9% Y/Y). Operating margin -4.1%, net loss $1.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $14.0M in Q3 2026, up 9% year over year and up 1% from the previous quarter.
Gross margin was 64.2%, down 0.3 points from Q3 2025. Operating costs exceeded revenue by $571K, an operating margin of -4.1%. Operating expenses grew 5% against revenue growth of 9%. The quarter ended with a net loss of $1.8M, narrower than the previous quarter's $3.1M loss. Minority interests bore $21K of it: to shareholders the quarter was a loss of $1.8M. Net interest and other expense of $1.1M was the main reason.
Operating cash flow was −$1.6M. Non-cash charges added back $187K of depreciation and amortization and $753K of share-based compensation. Working capital and other items used $768K. Capital expenditures of $265K exceeded it, leaving free cash flow of −$1.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $14.0M | +9% | -4.1% | −$1.8M | −$1.6M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $13.9M | +22% | -13.0% | −$3.1M | −$3.5M |
| Q1 2026 | 10-Q | May 7, 2026 | $12.5M | +32% | -7.3% | −$2.1M | −$572K |
| Q4 2025 | 10-K | Mar 10, 2026 | $19.2M | +35% | 0.1% | −$1.2M | −$2.5M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $12.9M | +12% | -6.5% | −$2.0M | −$3.5M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $11.4M | -6% | -22.6% | −$3.7M | −$1.2M |
| Q1 2025 | 10-Q | May 8, 2025 | $9.4M | -8% | -32.4% | −$4.2M | −$702K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Apyx Medical
Apyx Medical Corporation (“Company”, “Apyx Medical”, “we”, “us”, or “our”) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760. We are a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion ® and the AYON Body Contouring System TM (“AYON”) in the cosmetic surgery market and J-Plasma ® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. AYON is an FDA-cleared, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform.
In its own words, from its 10-K, filed Mar 10, 2026.
Apyx Medical against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +9% against the peers' median +5%. Operating margin: -4.1% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| APYX Apyx Medical | Q3 2026 | $14.0M | +9% | -4.1% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Apyx Medical 10-Q on SEC EDGAR · CIK 719135 · Surgical & Medical Instruments & Apparatus
13F: who owns APYX and who is buying
More on APYX
- How Apyx Medical makes money: revenue by segment
- Apyx Medical next earnings date and what analysts expect
- Apyx Medical stock forecast, price target and fair value
- Who owns Apyx Medical stock: holders, funds and Congress trades
- Apyx Medical guidance and outlook
- Apyx Medical recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results